Citadel Advisors
TCON

Citadel Advisors’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Citadel Advisors’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,235
Closed -$46.7K – 15464
2023
Q1 		$46.7K Sell
1,235
-840
-40% -$27.5K ﹤0.01% 12246
2022
Q4 		$61.8K Buy
2,075
+625
+43% +$18.9K ﹤0.01% 11878
2022
Q3 		$48K Sell
1,450
-840
-37% -$32.1K ﹤0.01% 11671
2022
Q2 		$92K Sell
2,290
-6,470
-74% -$250K ﹤0.01% 11496
2022
Q1 		$461K Sell
8,760
-570
-6% -$28.7K ﹤0.01% 9588
2021
Q4 		$517K Buy
9,330
+6,070
+186% +$387K ﹤0.01% 9618
2021
Q3 		$252K Buy
+3,260
New +$276K ﹤0.01% 11474

Other funds holding TCON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's TCON Position: Q2 2023 in Review

Citadel Advisors sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2023, closing a stake of 999 shares — an estimated $37.8K sold.

Citadel Advisors first reported a position in TCON in Q4 2017 and held it in 16 quarters. The position peaked at $144K in Q4 2020. 27 funds tracked by Wall St. Rank hold TCON as of Q2 2023.

  • Citadel Advisors reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 999 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $37.8K.
  • Citadel Advisors first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 16 quarters.
  • Citadel Advisors's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $144K in Q4 2020.
  • 27 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.